abused drugs
  addiction, 6, 52, 74, 75
designer drugs, 51
effects on nervous system, 6, 9, 51–53, 71
health costs of, 20, 53, 232
psychoactive drugs, 6, 10, 27, 44, 50
withdrawal from, 74
see also specific drugs
academic research
  cooperative agreements with government, 94
  factors influencing directions of, 92–94
acetaldehyde, 297
acetone, 14, 136, 296, 297, 303
acetylcholine, 26, 66, 109, 124, 294, 336
acetylcholinesterase, 11, 50, 74, 84, 187, 203, 289, 290–292, 336
acetyethyl tetramethyl tetralin (AETT)
  exposure route, 108
  incidents of poisoning, 47, 54
  neurological effects of, 54
acrylamide, 73, 120
  neurotoxicity testing, 166, 175
  regulation for neurotoxicity, 178
  risk assessment approaches, 150, 151, 216
  research on neurotoxicity, 258
acrylates, 175
acrylonitrile, 203
  neurotoxicity testing, 166, 173
OSHA health standards, 185
action levels for contaminants in foods, 164, 241–242, 336
“Adam,” 51
Administrative Procedure Act, 162
age/aging
  and exposure to neurotoxic substances, 269
  as a factor in animal studies, 107
  nervous system effects of, 8, 15, 54, 67, 152
  and neurobehavioral tests, 126
  and toxicity of chemicals, 15, 63, 152
see also children; elderly
Agency for Toxic Substances and Disease Registry, 135–136
  research activities of, 9, 11, 89, 188, 271, 322
Agent Orange, 295
Agricultural Pesticide Institute of the Philippines, 252
air pollutants
  hazardous, defined, 181
  lead, 273–274, 276, 281
  standards for, 181, 182, 185
see also Clean Air Act
Alar, 291
Alaskan Marine Mammal Tissue Archival Project, 133
alcohol and alcohol abuse, 4, 44, 115
  axonopathic effects, 73
  effects on fetus, 70, 124
  research on, 9, 11
  thiamine deficiency and toxicity of, 71
Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), research
  activities of, 33, 81, 88, 322
aldicarb, 47, 173, 251
aldrin, 250, 252, 292
allyl chloride, 303
aluminum, 48
  and Alzheimer’s disease, 54–55
  oxide, 14, 136
Alzheimer’s disease
  effects on hippocampus, 71
  environmental cause, 3, 6, 54–55, 70, 72
  research on, 259
American Academy of Pediatrics, 189
American Conference of Governmental Industrial Hygienists, 28, 151, 185, 186, 203, 302–303
American National Standards Institute, 185
ammonia, 14, 136
amphetamine, 74
amyotrophic lateral sclerosis
  characteristics of, 54
  environmental cause, 3, 6, 54–55, 70, 72
  incidence of, 54, 55
  research on, 259
anencephaly, 70
anilines and substituted anilines, 179
animal tests, 13
  accuracy and reliability, 106, 115
  advantages and limitations of, 105, 106, 111, 112, 114, 116, 120–121, 136, 137
  alternatives to, 121–125; see also in vitro neurotoxicity tests of BHMH, 55–56
biochemical markers, 117
choice of animals, 106–107, 109–110, 121, 152
in combination with in vitro tests, 13, 122, 124
cost factors, 106–107, 110, 222–225, 226, 227
cross-species comparisons, 115–116, 121, 148
design, 105, 106, 109–111
developmental neurotoxicology, 110, 111, 114, 116–117, 137, 165–166, 178
dosing regimen, 107, 110, 147–148
comparability with human testing, 115
EPA guidelines, 110
evaluating chemicals for neurotoxicity, 109–110
extent and duration of exposure, 108, 222, 225, 226
extrapolation to humans, 18, 82, 105, 121, 147, 148, 149, 153, 204
of food additives, 52
functional observational battery, 110, 111, 112, 136, 137, 178, 224–225, 226
hazard identification with, 147
housing conditions, 108–109
innovation impacts of, 226–227
longitudinal, 107
of MDMA, 51–52
motor activity, 110, 111, 112, 14, 136, 137, 178, 224–225, 226
Motron Electronic Mobility Meter, 113
multispecies, 107
neuropathological examination, 110, 111, 114, 136, 137, 178, 224-225,226
neurophysiology techniques, 118–121
neurotoxic esterase assay, 111, 136–137, 178
nutritional status of animals, 108
observational methods, 112–113
for organophosphorous pesticides, 110, 117–118
quality assurance in, 222-223
route of exposure, 108, 121, 222, 225
schedule-controlled operant behavior, 110, 111, 116–117,
136, 137, 178,224-225
temperature of environment, 109
tiered approach, 109-110
types of, 110-121
validation of, 109
antagonism, 65
antibiotics, 45, 70, 123, 125
anticancer drugs, 51, 73
antipsychotic drugs, 44, 50
Apion (with TOCP), incidents of poisoning, 47
Argentina
research on neurotoxicity, 258
use of banned pesticides in, 239
arsenic, 133, 182, 183, 185
aryl phosphates, 179
asbestos, 176, 180, 182
aspartame, 166, 198
application process, 315–318
claims of adverse effects, 18, 318–319
postmarketing surveillance, 318
aspartate, 71
Association of People for Practical Life Education, 252
astrocytes, 117
attentional disorders, 70, 229, 273
auditory system
substances affecting, 49, 119, 131, 135,272
testing of, 119
Australia, use of banned pesticides in, 239
axonopathy
causative agents, 73–74
defined, 67,336
axons, 72
development of, 67
effects of toxic substances on, 67, 69, 73, 295
functions of, 65-66,336
azidothymidine, 167
barium, 183
Basic Document on Regulations of Registration, Marketing and
Control of Agricultural Chemicals for Countries of
Central America, 253-254
Bayley Scales of Infant Development, Mental Development
Index, 155
behavioral effects, 70
Collaborative Behavioral Teratology Study, 115
defined in TSCA, 174
duration of exposure and, 70
EPA research on, 82
examples of, 46
of lead, 46, 229–230, 272, 273
of organic solvents, 298–299
of pesticide poisoning, 285
research needs on, 154
tests for, see neurobehavioral tests
see also operant behavior
behavioral teratology, 70, 114-116
Belgium, regulatory policies in, 246-247
Benton Visual Retention Test, 127
benzene, 14, 135, 136, 182,297,303
beryllium, 182
BHC, 252
BHMH, incidents of poisoning, 47,55-56
biochemical markers, 11,82, 84, 117
biological monitoring, 133-134
blood-brain barrier
drug passage through, 66-67
fetal, 70
structure and function, 336, 66-67, 73
blood vessels, neurotoxic substances acting on, 74,76
botulinum toxin, 45
Bourdon Wiersma Vigilance Test, 127
brain
aging, and structure of, 15, 67, 152
congressional resolution on Decade of the Brain, 330–331
development of, 67
opioid receptors, 74
regional differences in sensitivity to toxic substances, 68
structure and function, 66
brain damage
from abused drugs, 51,70
from lead, 271
from mercury, 131
from pesticides, 291
branistem auditory evoked responses, 119, 128
Brazil, pesticide misuse in, 251
buckthorn (Karwinskia humboldtiana), 74
B-bungarotoxin, 124
Bureau of Community Environmental Management, 277
n-butyl alcohol, 14, 136
cadmium, 48, 68, 74
monitoring of, 133, 134
research on, 257
California Birth Defects Prevention Act of 1984,289-290
camphenechlor, 250
Canada
human tissue monitoring, 132
regulatory policies and practices in, 245
research on neurotoxicity, 258
carbamate insecticides, 26,49,74, 175,287, 289–291, 293,295,
336
carbon disulfide
exposure limits for, 187, 303
neurological effects of, 73, 108, 298, 299
poisoning incidents, 256
releases, 14, 136
carbon monoxide
air quality standards, 181, 182
central nervous system effects, 181, 187
poisoning, 64,69, 181
research on neurotoxicity, 258
carbon tetrachloride, 297
carbonyl sulfide, 14, 136
carcinogenicity, 56
cassava (Manihot esculenta), 55

cell cultures
  defined, 123, 336
  mixed, 338
  monolayer, 124
  muscle cells, 124
  retinal neurons, 124

cell lines, 124, 125, 336

Center for Environmental Health, research activities of, 90-91

Center for Science in the Public Interest, 192

Centers for Disease Control
  acceptable levels for lead, 271
  human monitoring program, 133
  lead poisoning prevention program, 277
  research activities of, 9, 11, 12, 81, 322

central distal axonopathy, 74

central nervous system, 336
  degeneration, 72
  depression of activity, 108
  lead effects on, 272
  pesticide effects on, 284-285
  structure, 66

central-peripheral distal axonopathy, 67, 73–74

cerebellum, 67, 70, 72, 336

cerebral palsy, 49

cerebrum, 70, 336

charitable organizations, research by, 97

Chemical Industry Institute of Toxicology, 123-124

Chemical Specialties Manufacturing Association, 220

chemicals
  commercial, see industrial chemicals
  consumer, 17
  diversity of new products, 227
  high production, high exposure, 17, 178-179, 195, 197, 202, 204, 227
  licensing and registration of, 174-180, 197, 202
  low production, low exposure, 178, 227-228
  neurotoxic, classes of, 175
  neurotoxicity tests and innovation in, 227-228
  new v, existing, consistency of regulation, 17, 18, 196-198
  patent protection, 226
  premanufacture notices, 17, 174-176, 194, 196, 197, 201-202, 219-220, 227, 247
  priorities for testing, 178
  reporting of harmful effects of, 180, 197
  significant new use rule, 174
  subject to neurotoxicity evaluation under TSCA, 179, 202
  testing of, 174-175, 232
  see also neurotoxic substances; organic solvents; and specific chemicals

chemoreceptors, 65

children
  lead poisoning in, 7, 8, 46, 70, 72-73, 181, 229, 267, 268-271, 273, 275, 278
  mental disorders in, 8, 45, 70, 73
  number exposed to lead, 269, 271
  pesticide risks to, 25, 283, 284, 293
  vulnerability to neurotoxic substances, 8, 45, 267, 268, 283
  chlordane, 238–239, 250, 252, 292
  chlordane, incidents of poisoning, 47, 50, 293
  chlordecone, 120, 250
  chlorine, 14, 136
  chlorofluorocarbons, neurotoxicity testing, 166
  chloroform, 14, 136, 303
  chloroquine, 124
  chlorphenoxy herbicides, 294-295
  cholinesterase inhibitors, see acetylcholinesterase; organophosphorus pesticides
  chromium, 133

Clean Air Act, 135
  1970 amendments, 180
  amendments proposed, 26, 182, 280
  cost-benefit analysis under, 216
  definition of hazardous air pollutant, 181
  lead regulation under, 273
  regulatory authority, 23, 160, 162
  risk assessment approach, 160
  standard setting under, 180-182
  toxic substances regulated by, 160

Clean Water Act, 26
  regulatory authority, 16, 23, 160
  risk assessment approach, 160
  standard setting under, 180, 182-183, 187
  toxic substances regulated by, 160

clioquinol, incidents of poisoning, 47, 74

cocaine, 9, 44, 115
  effects on nervous system, 6, 52, 74-75
  fetal effects of, 10, 53, 70, 74

Cognitive Scanner, 128

Colombia, use of banned pesticides in, 239, 243

Color Additive Amendments of 1960, 165

color additives, see food and color additives

Comprehensive Drug Abuse Prevention and Control Act, 188

Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), 26, 198
  control measures under, 187-188, 280-281
  regulatory authority, 16, 23, 161
  risk assessment approach, 161
  toxic substances regulated by, 161, 280-281
  see also Superfund Amendments and Reauthorization Act

computer-based testing, 127–128, 137

confidence, trade secret protection and testing, 19, 25, 176, 202, 218, 226, 288

Consumer Product Safety Act (CPSA), 172
  regulatory authority, 16, 160
  reporting requirements for adverse effects, 204
  risk assessment approach, 160
  standard setting under, 180, 184
  toxic substances regulated by, 160

Consumer Product Safety Commission (CPSC), 176
  in vitro testing by, 122
  policy issues and options for, 31
  regulatory authority of, 160, 161, 184, 190, 191, 268
  research activities of, 323
  risk assessment applications, 150
  standard setting by, 184, 276

Consumers Association of Penang, 252
control-oriented measures
under CERCLA, 187–188
under Controlled Substances Act, 188
economic incentives, 161
features of laws, 159, 161
under bad-Based Paint Poisoning Prevention Act, 189–191
under Marine Protection, Research, and Sanctuaries Act, 188–189
under Poison Prevention Packaging Act, 189–191
regulatory approach, 16, 159
under Resource Conservation and Recovery Act, 191
Supported Substances Act
control measures under, 187, 188
regulatory authority, 16, 161
risk assessment approach, 161
toxic substances regulated by, 161
cosmetics
antidandruff shampoos, 108
color additives in, 165
dermal exposure to toxic substances, 108
fragrances, 108
incidents of neurobehavioral toxicity, 54
licensing and registration of, 168
regulation of, 54
testing, 17, 28, 52, 54, 168, 196
cost-benefit analysis
competing interests in, 56
costs defined, 214, 215
defined, 336
economic principles of, 221
effect on environmental policymaking, 220–221
Executive Order 12291 requirements, 212, 214–216, 220, 221
under FIFRA, 216, 286
health costs in, 228–230
knowledge requirements for estimating benefits, 228
for lead, 216
net efficiency, 215, 338
risk reduction, measures of, 215
in standard setting, 181
under TSCA, 216
unit of value in, 221
cost-effectiveness analysis, 214, 220, 221, 336
Costa Rica regulatory issues in, 253–254
costs of testing
in animal studies, 20, 106–107, 110, 111, 112, 116, 222–225
drug and pesticide development and, 225–227
estimates of, 20, 224–225, 231
fees, 223
financial determinants, 106, 223–224
general and administrative rates, 223
in vitro methodologies, 122
and innovation, 217–218, 225–228
labor rates, 222, 223–224
laboratory automation and, 116, 223
laboratory capabilities and, 223
overhead rates, 223
personnel, 223
protocol and, 222
quality assurance, 222–223
reregistration of pesticides, 241
scientific determinants, 222–223
under TSCA, 217
dioxin, 180, 294
diphenylhydantoin, 115
diphtheria toxin, 74
Dominican Republic, use of banned pesticides in, 239
domoic acid, incidents of poisoning, 47
dopamine, 66, 72, 336
depletion of, 6, 109
effects of cocaine on, 52, 74
dose
acceptable daily intake, 148, 336
behaviorally effective, 116
defined, 337
extrapolation from high to low, 148, 154, 200
reference (RfD), 116, 148–149, 150, 153, 340
regimen in animal tests, 107, 110
threshold, 14, 147, 151, 153, 162, 185, 203, 341
and toxicity, 6, 44, 70, 108, 150, 283, 290
see also no observed adverse effect levels; no observed effect levels
dose-response assessment
from automated motor activity measures, 113
defined, 63, 337
extrapolation of doses, 147
issues in, 107, 153–154
methods, 111, 118, 147–148
NOAEL versus NOEL, 147–148, 153
in risk assessment, 147–148
safety factors, 147, 148, 149, 153–154, 155
thresholds and RfD approach, 153, 155
Down’s syndrome, 71
doxorubicin, 73
drinking water
hazardous wastes in, 198
lead in, 216, 230, 269, 277–279
regulations to control contaminants, 183–184, 216, 277–279
from water coolers, 279, 280
Drug Price Competition and Patent Restoration Act, 226
drugs
axonopathy from, 73
color additives in, 165
development, 219, 225–226, 231–232
neurotoxic potential, 43
neurotoxicity testing and innovation in, 226–227
passage through blood-brain barrier, 67
see also abused drugs; therapeutic drugs; and specific drugs
economic issues, 56
analysis of regulations, 213–221, 230
benefits of regulating neurotoxic substances, 20, 228–231, 232
cost-benefit analyses, 20, 211, 214–215, 220–221, 337
cost-effectiveness analyses, 214–215, 220, 221, 337
in design of animal experiments, 106, 222–223
economic efficiency, 56, 214–216
innovation incentives and disincentives, 20, 218–220, 225–228
market prices and profitability and costs of regulation, 217–218
opportunity costs, 221, 228
regulatory analyses, 20, 211, 214–215, 218 n.11, 220–221
regulatory impact analyses, 211, 214, 231
risk assessments, 211, 231
risk-benefit analyses, 20, 211, 216–217, 218 n.11, 340
in standard setting, 199
see also costs of testing; health costs of neurotoxicity; risk assessment
“ecstasy,” 9, 51
Ecuador
pesticide import problems, 243
regulatory issues in, 255–256
education
of health-care professionals, 97–100
of research scientists, 97, 259
of workers, 30, 287
Egg Products Inspection Act, 241, 242
elderly, vulnerability to neurotoxic substances, 8, 45
electroencephalograph, 119
electromyography, 128, 337
electroneurography, 128, 337
electrophysiological testing, 82, 337
electroencephalograph, 119
macroelectrode, 118
microelectrode, 118
multitunit electrode, 118
of muscle cells, 124
encephalitis, 74
encephalopathy, 74, 181, 337
endorphin, 66, 74
endpoints, 337
for emission standards for hazardous air pollutants, 182
in risk assessment, 15, 149, 150, 151, 152, 153
for toxicity testing, 109, 116, 125, 150, 152, 178
for water quality criteria, 182–183
drin, 47, 183, 250, 255, 292
enkephalin, 66, 74
environmental hypothesis, 54–55, 70, 72, 337
Environmental Protection Agency (EPA), 56, 177
Clean Air Scientific Advisory Committee, 271
coordination of regulatory efforts within, 191–192, 198
core test battery, 13, 20, 23–24, 110–111, 114, 137, 152, 178,
179, 224, 231, 287
definition of neurotoxicity, 44
developmental neurotoxicology workshop, 115
economic assessment of regulations, 213, 218
health advisories, 183–184
impact analysis of regulations, 220–221
Integrated Risk Information System, 198
labeling criteria, 172
monitoring activities, 132, 133
Neurotoxicology Division, 81–84
Office of Drinking Water, 183
Office of Environment Criteria and Assessment, 187
Office of Mobile Sources, 182
Office of Pesticide Programs, 110, 135, 170–172, 191–192,
203, 216, 287
Office of Program Planning and Evaluation, 198
Office of Solid Waste Management, 198
Office of Toxic Substances, 110, 152, 174, 176, 177, 191–194,
197, 198, 200, 201, 216
Office of Water Regulations and Standards, 182
pesticides registered with, 49
policy issues and options relevant to, 23–27, 31–32
policy on neurotoxicity testing, 178
regulatory authority of, 15–16, 26, 23, 160–162, 164,
neurotoxicity: Identifying and Controlling Poisons of the Nervous System

170-177,179-182,187, 189,197,212,227 n. 16,241,267
research activities, 9, 11, 31–32, 81–84, 323
Risk Assessment Forum, 11
risk assessment guidelines, 116, 146, 150, 192, 216
Science Advisory Board, 81,82,84
Scientific Advisory Panel, 110-111, 115, 173,288
standard setting, 180-183
testing guidelines, 13,110-112,114-118, 136,137, 177–179,
191-193,200,201,222, 287
Tolerance Assessment System, 135
Toxics Release Inventory, 3,43, 122, 134-136, 195

epidemiological studies, 337
advantages and limitations of, 125, 128
computer-based neurobehavioral tests for, 127
geographical isolates of neurological conditions, 259
hazard identification with, 147
industry-government cooperation on, 96
international activities in, 259
need for, 55, 154
occupational, 129–130
of pesticide poisoning, 285, 295
specimen banking for, 132
erythrosin, 166
ethanol, see alcohol and alcohol abuse
ethical issues
exports of toxic substances, 56-57, 243, 245, 261
human testing and monitoring, 125, 130, 136
manufacturers’ duty to follow products to consumers, 249
Ethiopia
lathyrism in, 55
research on grass pea neurotoxicity, 259
eythyl acetate, 297
eythyl ether, 297
eythyl nitrate, 297
eythyl parathion, 250, 251
eythyl toluenes, 179
eythylene, 14, 136
eythylene dibromide, 250
eythylene dichloride, 303
eythylene glycol, 297
eythylene oxide, 185
eythyl-p-nitrophenyl phosphonothionate, 203
risk assessment approaches, 150, 151, 173
European Economic Community, testing guidelines, 115
evoked potentials, 337
brainstem auditory, 119
flash, 119
pattern reversal, 119
somatosensory, 118–1 19, 120-121
visual, 119–120
excitotoxicity, 71

Executive Order 12264, control of exports of hazardous substances, 57, 240-241, 260
Executive Order 12291
cost-benefit analyses under, 212, 215–216, 220
inflation considerations in, 217 n.9
requirements of, 213–214
exports of toxic substances
consent requirements, 240
Executive Order 12264,57,240-241
famine as justification for, 243,245,261
international effects of U.S. practices, 21–22, 242–245
labeling violations, 242–243
notification requirements, 22, 239–240, 247, 261, 339
pesticides, 56-57,237, 241–245, 249–250, 261
repackaging problems, 243
testing requirements, 240
U.S. laws, 239-241,261

exposure to neurotoxic substances
acute, 26, 108, 111, 114, 116, 125, 148, 222, 224,272, 292,
294,296,336
additive effects, 44
in animal tests, 107–108
assessment of, 132, 148; see also Monitoring of toxic substances
chronic, 26,44, 114, 116, 125; 148, 152,222,244,256,257,
272,291,294,296,336
defined, 337
dermal, 107, 108,292-293,294-295, 296,298
extent and duration, 4,44,67-68,73, 107, 108,125, 133,148,
152,222,337
human studies of, 128-131
inhalation, 107, 108, 269, 292,293, 296, 298
margin of (MOE), 149
oral, 107, 269, 292, 298
OSHA limits for mercury, 131
pattern of, 148, 178, 339
prevention of, 130-131
risk to humans, 43
routes of, 6, 63, 64, 107–108, 121, 125, 131, 148, 222, 224,
231,269,283,290,293, 298,340
subacute, 108
subchronic, 108, 111, 114, 148, 149, 340
see also dose; occupational exposures; and specific substances

Eysenck Personality Inventory, 127

famine, and pesticide use, 243,245,253,261
Faroe Islands, 259
Federal Emergency Planning and Community Right-to-Know Act of 1986, 13, 134
Federal Environmental Pesticide Control Act, 170,213
Federal Food, Drug, and Cosmetic Act (FFDCA), 56, 172,213
1962 amendments, 217,219
amendments proposed, 168
color additive regulation, 164-166
cosmetics regulation, 17, 168
Delaney clause, 17, 195
drug review and regulatory process, 16, 29, 51, 166-169,
221-222
economic balancing provisions of, 212
environmental contaminants of food, 163–164
food additive regulation, 52, 164-166
licensing and registration under, 27,29, 161, 163–169
notification requirements, 218
pesticide residue standards, 164,241
regulatory authority, 16, 160, 213
reporting requirements for adverse reactions, 167,203
risk assessment approach, 160
risk-benefit analysis under, 216
tolerance setting, 216
toxic substances regulated by, 160
Federal Hazardous Substances Act, 172
definition of hazardous substance, 184
regulatory authority, 16, 160
risk assessment approach, 160
standard setting under, 180, 184
toxic substances regulated by, 160, 190
Federal Insecticide Act, 168
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 56, 172, 213
1972 amendments, 170, 219, 285-286
1988 amendments, 18, 171, 192, 197, 217, 287, 288
amendments proposed, 24, 26
coordination of TSCA neurotoxicity evaluations with, 191–192
definition of pesticide, 281-282
economic balancing provisions of, 212, 216, 286
export controls, 21-22, 239, 240, 261
extent of testing under, 17, 18, 24, 203, 221–222, 287
generic testing guidelines, 115, 136, 171, 192
licensing and registration under, 17, 16, 29, 161, 169-173, 194, 199, 201, 203, 204
new pesticide registration, 17, 164, 170-171, 194
notification requirements, 218, 238, 240
pesticide residues in food, 241
protection of workers under, 285-287
regulatory authority, 16, 23, 26, 160
reregistration of existing pesticides, 17, 171–173, 286, 287
risk assessment approach, 160
risk-benefit analysis under, 216, 286
Science Advisory Panel, 192
tolerance setting, 27, 164
toxic substances regulated by, 160
Federal Interagency Hazardous Substances Export Policy Task Force, 57
Federal Meat Inspection Act, 241, 242
Federal Mine Safety and Health Act
regulatory authority, 16, 161
risk assessment approach, 161
standard setting under, 180, 185, 186
toxic substances regulated by, 161
Federal Republic of Germany
human tissue monitoring, 132
neurotoxicity testing approach, 24
regulatory policies in, 22, 245–246, 260, 261
researcher mining, 259
Federal Water Pollution Control Act
regulatory authority, 16, 23, 160
risk assessment approach, 160
standard setting under, 180, 182–183
toxic substances regulated by, 160
Federation of American Societies for Experimental Biology, testing recommendations of, 114, 193
fenvlurate, 113
fetuses
alcohol effects, 70, 124
antibiotic effects, 70
cocaine effects, 9, 10, 52, 53, 70, 74
lead effects, 272
nervous system development, 67
mercury poisoning, 49, 152
steroid effects, 70
therapeutic drug effects, 51, 73
vulnerability to neurotoxic substances, 8, 45, 49, 70, 269
Finland, Institute of Occupational Health neurotoxicity test, 126
flash evoked potentials, 119, 128
food
action levels for contaminants in, 164
adulterants, 241
imports, 239, 241–242, 250
lead in, 274-275
pesticide residues in, 241-242, 250, 260
regulation of environmental contaminants of, 163–164
Food Additives Amendment of 1954, 164
food and color additives
adverse effects claims, 318
appeals of decisions, 31, 317
application, 315
approval process, 315-319
lead in, 275
licensing and registration process, 52, 164-166
postmarketing surveillance, 318
preapplication, 315
regulation of, 17, 52, 161, 195, 204
review, 203, 315
testing for neurotoxicity, 18, 27, 52, 166, 199, 204
Food and Drug Administration (FDA), 56
analytical methods for pesticide detection, 50
Center for Biologics Evaluation and Research, 167
Center for Drug Evaluation and Research, 167, 168, 198, 201
Center for Food Safety and Applied Nutrition, 12, 165-166, 192–194
color additive regulation, 192–194
cosmetic regulation, 54
drug review and regulatory process, 51, 199
economic assessment of regulations, 213
food additive regulation, 52, 192-194
interpretation of safety, 165
monitoring system for adverse drug reactions, 29, 168, 169, 198
neurotoxicity testing by, 27, 166
policy options for, 27-28, 33-34
Priority-Based Assessment of Food Additives Program, 198
research activities of, 9, 12, 33–34, 81, 88-89, 122, 323
risk assessment applications, 150
testing guidelines, 27, 51, 167–168, 192–194, 199-200, 204
Total Diet Study, 135
Food and Drugs Act of 1906, 163
Food Safety Amendments of 1989, 168
France
regulatory policies in, 247, 259
research on neurotoxicity, 258
Freon 12, 166
Freon 113, 14, 136
fufuryl alcohol, 303
fumigants, neurotoxic, 293-294
functional observational battery
advantages and limitations, 11, 1–112
costs of, 20, 224-225, 226, 231
defined, 337
in EPA core test battery, 13, 111, 136, 204
EPA guidelines for, 110, 111, 178
FDA approach, 193
OECD guidelines, 194
fungicides, mercury, 48, 257

Galecron, 250
Gammalin 20, 252
ganglion, 124, 337
General Accounting Office, 220
Generally regarded as safe (GRAS) compounds, 27
Ghana
Lake Ghana pesticide poisoning incident, 252
regulatory issues in, 248
Ginger-Jake syndrome, 47, 69
glial cells
development of, 67
effects of toxic substances on, 67
function of, 65, 124, 337, 339
neurotoxic substances acting on, 74
glial fibrillary acidic protein (GFAP) radioimmunoassay, 117
Global Environment Monitoring System, 134
glue-sniffing, 48; see also inhalant abuse
glutamate, 71, 124
glycol ethers
releases of, 14, 136
toxicity of, 175
testing of, 115, 135
grass pea, 55, 259
Guam ALS-Parkinson’s dementia, 54, 70, 74, 259
Halcion, FDA monitoring of adverse reactions to, 29, 169
hazard identification, 147, 152, 154
hazardous wastes
defined, 187, 191
in drinking water, 198
registry of persons exposed to, 135–136
health-care professionals
education of, 97–100
see also nurses; industrial hygienists; physicians
health costs of neurotoxicity
dementia, 229
of drug abuse, 20, 53
exposure to lead, 20, 229–230
mental disorders and nervous system diseases, 229
personal health-care expenditures, 20–21, 229
health effects
“adverse” defined, 7, 4445, 115–1 16, 145, 162, 167, 170, 212, 228
delayed, 50, 54, 70, 107, 117, 118, 151–152, 155, 194
“harmful,” 145, 147
nutritional status and, 70, 72
reversibility of, 15, 46, 69, 71, 107, 108, 151, 152, 290
secondary, 45, 72
health status, and neurotoxicity, 8,70–71, 108, 290
heavy metals
assessment of effects of, 119, 124
effects on nervous system, 74
monitoring of, 135
research on, 256, 258
toxicity of, 46, 71; see also specific metals
hen test, see neurotoxic esterase assay
heptachlor, 238, 250, 292
heroin, 6, 9, 44, 72, 74
hexachlorobenzene
effect on nervous system, 74
incidents of poisoning, 47
hexachlorocyclohexane, 250
hexachlorophene, 45
n-hexane, 73, 124, 297, 299
incidents of poisoning, 47
neurotoxicity testing, 179
regulation of, 184
risk assessment approaches, 150, 151
2,5-hexanediol, 124
hippocampus
functions and structure of, 68, 71
PCP effects on, 71
trimethyltin damage to, 68, 74
Hispanic Health and Nutrition Examination Survey, 132
Honduras, pesticide-contaminated exports, 238–239
Human Nutrition Information Service, 135
human testing and studies, 105, 336
computerized techniques, 13, 127–128, 137
confidentiality, 130
consent and disclosure requirements, 130
examiner-subject interaction, 128–129
exposure studies, 128–131, 256
extrapolation of results to other populations, 147, 153
of food additives, 52
Institutional Review Boards, 130
for lead exposure, 270
legal and ethical considerations, 12, 125, 130
limitations of, 147
neurobehavioral, 13, 125–126, 137
neurophysiological techniques, 13, 128, 137
selection of study populations, 105, 129
of therapeutic drugs, 52
types of, 125–128, 137
workplace research, 129
see also epidemiological studies
hydrocarbons, 182
hydrochloric acid, 14, 136
hydroquinone, 179
imidazoles, 175
imports
and “circle of poison,” 22, 57, 238, 250, 260, 261
controls in developing countries, 250–255
see also exports of toxic substances
in vitro tests, 338
advantages and limitations of, 12–13, 56, 105, 118, 122, 124–125, 136
application to neurotoxicity testing, 122, 123–124
cell lines, 124
costs of, 122
development of, 11, 12–13, 84, 122, 137
primary cultures, 123–124
screening with, 13, 110
validation of, 123–124
see also tissue culture, 122, 123
incinerator ash
exports of, 240
lead in, 268, 279–280
India
Bhopal accident, 243
grain surpluses, 243
Index

regulatory activities in, 253
research on neurotoxicity, 258
Indonesia, pesticide misuse in, 251
industrial chemicals
axonopathy from, 73
incidents of poisoning, 47,48-49
licensing and registration of, 16,161,174-180,195,196, 204;
see also Toxic Substances Control Act
neurotoxic potential, 3,43, 48,259
see also chemicals; organic solvents; and specific chemicals
industrial hygienists, education of, 99
industrial research, 12
by consumer product industry, 95
government-industry consortia, 96
industry consortia 96
by pesticide industry, 94
by pharmaceutical industry, 95
industrialized countries
imports of contaminated food, 238
regulatory policies in, 245–248, 260
see also specific countries
inert ingredients, neurotoxicity evaluations, 24,288
inhalant abuse, 48, 49, 296, 299-300
innovation
chemical R&D, 219–220, 227–228
costs of neurotoxicity testing and, 225–228
drug R&D, 219,225-226
input measures, 219
output measures, 219
pesticide R&D, 219,226-227
regulation and incentives for, 20, 218–220
integrated pest management, 243, 290, 291, 295, 337
Inter-American Institute for Cooperation on Agriculture, 253-254
interaction of toxic substances
additive effects, 44, 64
antagonism, 65
drugs, 8-9,29,45, 169
potentiation, 65
synergistic effects, 64, 65
sources of complex mixtures, 65
Interagency Testing Committee, 177–178, 202
Interagency Working Group on Neurotoxicology, 19
International Group of National Associations of Manufacturers of Agrochemical Products, 243, 255
international issues, 21, 56-57
effects of U.S. export practices, 242–245
monitoring of toxic substances, 132, 134
neurotoxicological research, 256-260
pesticide residues in domestic and imported food, 241-242
regulatory activities, 21–22, 115, 237–256
regulatory issues in developing countries, 248–256
regulatory policies in other industrialized countries, 245–248
testing guidelines, 191
U.S. export laws, 239-241
U.S. regulation of neurotoxic substances, 239-245
see also developing countries; exports of toxic substances; imports
International Neurotoxicology Association, 256,258
International Program on Chemical Safety, 242
International Rice Research Institute, 252-253
ion channels, 7, 66, 72, 118, 295
Iraq, mercury poisoning in, 47,48,49,243,257
isopropanol, 179
Italy
research on neurotoxicity, 258, 259
researcher training, 259
Japan
human tissue monitoring, 132
mercury poisoning in Minamata Bay, 47,48,247, 257
regulatory policies in, 247–248, 259
research on neurotoxicity, 258, 259
kainic acid, 124
Kenya, regulatory issues in, 256
Kepone, incidents of poisoning, 47,50,293
Kuhnburg Figure Matching Test, 127
labeling, 29,44, 169, 171
of cosmetics, 28
effectiveness of regulatory requirements, 172
of hazardous substances, 184, 187, 247, 248
incidents of poisoning resulting from violations of, 242–243
with pictograms, 243–244
WHO requirements, 249
latent effects, 50,54, 70, 107
acute delayed neurotoxicity, 118
defined, 338
of organophosphates, 117–1 18, 194, 199,204,284,290-291, 295
and risk assessment, 15, 151-152, 155
subchronic delayed neurotoxicity, 118
lathyrism, 55
lead
in air, 273–274, 276, 281
cost-benefit analyses, 20, 216, 230-231,232
in drinking water, 8,216, 221,230,231,267,269, 277–279, 281
effects on human body, 229–230, 271–273
estimates of exposure, nationally, 230
Federal regulation of, 8,46, 182, 183
in food, 267, 269, 274-275, 281
in gasoline, 216,221,230,231,257, 267,269, 273–274, 275, 281
health benefits of reducing neurotoxic effects in children, 231, 232
in incinerator ash, 279–280
levels of exposure, 270-271,274,281
MCLs, 183
monitoring programs, 133, 134
neurological effects of, 6,8,46,56,72-73,74, 150, 162, 181, 185
occupational exposures, 269,276
OSHA health standards, 185
in paint, 8, 184, 189–191, 257, 267–269, 276-277
PELs, 276
in pesticides, 274
regulatory activity, 211,213, 267, 273–281
research on toxicity, 256-257, 258, 259
Neurotoxicity: Identifying and Controlling Poisons of the Nervous System

- risk assessment approaches, 150, 151
- routes of exposure, 269
- screening method for humans, 270
- sites of accumulation in the body, 64
- in soil, 269, 280-281
- sources of exposure, 8, 267, 267-269, 273
- standard setting, 181-181, 184, 189, 276, 277, 281
- threshold for, 162, 267, 270-271, 281
- water quality standards, 183, 281
- see also lead poisoning

Gad-Based Paint Poisoning Prevention Act (LBPPPA)
- amendments, 189, 190
- control measures under, 187, 189-191, 276-277, 280
- regulatory authority, 16, 161
- toxic substances regulated by, 161

Lead Industries Association, Inc., 162, 182 n.8
- lead poisoning, 45, 115
  - case studies, 267-281
  - chelation treatment, 271-272
  - in children, 7, 8, 46, 70, 72-73, 155, 181, 184, 229, 260, 267, 268-271, 273, 275, 276, 281
  - cognitive development and, 7, 8, 44, 46, 70, 73, 155, 273
  - costs of, 229-230
  - duration of exposure and, 44, 270-271
  - economic status and, 271
  - historical perspective on, 268
  - incidents of, 47
  - mortality from, 271-272
  - prevalence of, 267, 268
  - prevention of, 8, 189-190, 277, 278, 280, 281
  - research on, 260
  - sources of, 256-157
- learning disorders, 46, 70, 181, 230, 283, 293
  - tests of, 193

legal issues
- challenges to EPA standard-setting authority, 162
- in human testing and monitoring, 130
- labeling requirements, 172

legislation
- diversity of, 159, 211, 213
- export, 237-241
- interpreting language of, 162
- key features of laws regulating toxic substances, 160-161
- major statutes, 23; see also specific statutes
- see also control-oriented measures; licensing and registration; regulations and regulatory issues; standards and standard setting

leptophos, incidents of poisoning, 47
- levodopa, 72

licensing and registration
- application and review processes, 161, 163
- chemicals, 161, 174-180
- of color additives, 164-166
- of cosmetics, 168
- of drugs and biologics, 29, 161, 166-169
- environmental contaminants of food, 163-164
- features of laws, 159-160
- under Federal Food, Drug, and Cosmetic Act, 29, 161, 163-169, 194, 218
- under Federal Insecticide, Fungicide, and Rodenticide Act, 161, 168, 170-173, 194, 218
- of food additives, 161, 164-166
- implementation of, 159
- neurotoxicity testing for, 161, 163
- of pesticides, 164, 161, 170-173
- regulatory approach, 16, 159
- risk-benefit analyses, 216
- under Toxic Substances Control Act, 173-180, 194
- lindane, 183, 250, 252, 292
- lipophilicity of chemicals, 44, 64, 298, 338
- locus ceruleus, 67
- Lou Gehrig’s disease, 54, 70
- LSD, 51, 74
- Lucel-7, 47, 55-56, 73

malathion, 251, 284
- Malaysia, regulatory issues in, 250-252
- manganese, 47, 48, 257
- manganese madness, 48
- mania, 71
- margin of safety, 338
- EPA interpretation, 180-181
- risk assessment approaches, 149, 162
- marijuana, 10, 53
- Marine Protection, Research, and Sanctuaries Act (MPRSA)
  - control measures under, 187, 188-189
  - regulatory authority, 16, 23, 161
  - risk assessment approach, 161
  - toxic substances regulated by, 161
- Materal and Child Health Services Block Grant, 277, 280
- maximum contaminant levels (MCLs) and maximum contaminant level goals (MCLGs), 183, 198, 278-279, 338
- MDMA, effects on nervous system, 9, 51-52
- mental disorders
  - in children, 45, 70
  - costs of, 20, 229
  - exacerbation of, 71
  - retardation, 70, 73, 272
- meperidine, 51, 106
- 2-mercaptobenzothiazole, 179
- mercury
  - delayed effects of, 152
  - effects on nervous system, 72, 74
  - emission standards, 182
  - incidents of poisoning, 45, 49, 131, 247, 257
- MCLs, 183
- monitoring programs, 133
- ocean dumping restrictions, 189
- OSHA exposure limit, 131
- research on toxicity, 257
- routes of exposure, 131
- symptoms of exposure, 48, 49, 131
- testing for, 124
- and water quality standards, 183
- mescaline, 74
- methadone, 115
- methanol, 14, 136, 186-187, 203
- methomyl, 284
- methoxychlor, 183
- methyl alcohol, 296, 297
- methyl bromide, 255, 294
- methyl chloride, 166
methyl chloroform, 303
methyl ethyl ketone, 14, 136
methyl ethyl ketoxime, 179
methyl tin, 166
methyl-n-butyl ketone, 299
incidents of poisoning, 47, 49
releases of, 14, 136
route of exposure to, 108
2-methyl-4-chlorophenoxyacetic acid, 294
methyl-tert-butyl ether, 179
methylcyclohexane, 299
methylcyclopentane, 299
methylene chloride, 296, 298
methylmercury, 15, 48, 49, 115, 152, 243, 257, 258
mevinphos, 284
Mexico
pesticide import problems, 243
regulatory issues in, 254-255
research on neurotoxicity, 258
MicroTox System, 128
Milan Automated Neurobehavioral System, 127
Minamata Bay, Japan, methylmercury poisoning, 47, 48, 247
Mine Safety and Health Administration, 161, 185
Minerals Management Service, 133
Mira Test, 127
mirex, 292
monitoring toxic substances
adequacy of regulatory structure determined through, 203–204
animal tissues, 132
biological programs, 13, 132, 133-134, 137
for cholinesterase inhibition, 84, 287, 289
coordination of programs, 325–326
FDA postmarked system for adverse drug reactions, 28, 29, 168, 169, 198
in human tissues, 132, 137
legal and ethical considerations, 130
mechanisms, 13, 203–204
need for, 13, 30, 289
neurophysiological techniques, 128
occupational exposures, 13, 30, 131, 133
pesticides, 132, 133, 134, 135, 241, 242, 251-255, 289, 296
purpose of, 133
specimen banking, 132–133, 137
worker safety programs, 131
see also Toxics Release Inventory
monoamine oxidase inhibitor, 6, 72
monohalomethanes, 123–124
mood and personality, effects of neurotoxic substances on, 46, 230, 283, 285
morphine, 74
mortality
abused drugs, 51, 52
mercury poisoning, 47, 48, 49
motor neuron disease, 54
Parkinson’s disease, 3, 54, 55
from pesticide poisoning, 250, 251, 283, 285
motor activity
animal tests of, 13, 20, 110, 111-114, 116, 118, 136, 178, 224-225, 226, 231, 338
defined, 111-112
effects of neurotoxic substances on, 46-50, 53, 72, 109, 117, 118, 123, 131, 271
as an indicator of neurotoxicity, 112, 116, 194
mechanical recording of, 113
observational analysis, 112–113
sensory systems and, 70
specificity of measures, 114
see also screening
motor neuron disease, 54, 55
motor neurons, 66, 70, 74
MPTP
animal model for experiments, 106
effects on nervous system, 51, 54
incidents of poisoning, 47, 70
and Parkinson’s disease, 6, 51, 54, 72
multiple sclerosis, 70, 120, 259
myelin/myelin sheath
aging and, 67
assessment of effects of neurotoxic substances on, 124
destruction of, 336
effects of toxic substances on, 67
function of, 65, 66, 338
neurotoxic substances acting on, 74
myelinopathy, 67
National Academy of Sciences, 8, 45
proposed study by, 27
risk assessment recommendations, 146-147
testing recommendations of, 114, 116
National Aeronautics and Space Administration, research activities of, 9, 11.92
National Agricultural Chemicals Association, 255
National Ambient Air Quality Standards, 180-181
National Association for Perinatal Addiction Research and Education, 10.53
National Bureau of Standards, monitoring activities, 132
National Cancer Institute, 86, 177
National Center for Education in Maternal and Child Health, 277
National Center for Health Statistics
HHANES, 132
NHANES II, 132, 230 n.19
NHANES III, 132–133
National Environmental Specimen Bank, 132
National Health and Nutrition Examination Surveys
II, 132, 230 n.19
III, 132–133
National Human Adipose Tissue Survey, 133
National Institute on Aging, research activities, 86-87
National Institute on Drug Abuse, 9, 53
developmental neurotoxicology workshop, 115
research activities of, 87-88
National Institute of Environmental Health Sciences, 11, 85, 177
National Institute of Mental Health, research activities, 88
Neurotoxicity: Identifying and Controlling Poisons of the Nervous System

National Institute of Neurological Disorders and Stroke, research activities, 11, 84–85
National Institute for Occupational Safety and Health (NIOSH), 45, 56, 177
Educational Resource Centers, 99-100
protective measures recommended by, 30, 296
research activities of, 12, 34-35, 89–90
standard setting by, 28, 185, 186, 198–199
testing recommendations, 126
National Institutes of Health (NIH)
policy issues and options, 32-33
research activities, 9, 11, 32–33, 81, 84-87, 122, 321–322
see also specific institutes and programs
National Library of Medicine, research activities, 87
National Oceanic and Atmospheric Administration, tissue monitoring program, 133
National Primary Drinking Water Regulations, 183, 191, 278, 338
National Research Council, 146-147
National Residue Program, 135
National Science Foundation, 177
National Status and Trends Program for Marine Environment Quality, 133
National Toxicology Program
in vitro test development, 122
research activities, 22, 85–86, 259, 261
Nationwide Food Consumption Survey, 135
Natural Resources Defense Council, 282
naturally occurring toxic substances
in algae, see saxitoxin
in buckthorn, 73–74
cassava, 55
cycad, 54, 74
drought-resistant grass pea, 55
effects of, 54-55
in puffer fish, see tetrodotoxin
scorpion toxin, 72
neuritis, 68
nerve gas, 50, 74
nervous system
adult-stage modifications, 67
centrals with aging, 8, 67
development of, 8, 67
diseases, 54, 229; see also specific diseases
effects of toxic substances on, 67–71; see also symptoms of toxicity
immune system interaction with, 71
functional changes due to toxic substances, 69–70
lesions, 172
pesticide effects on, 283-285
structural changes due to toxic substances, 67-69, 267
structure, 43, 65-67
vulnerability to toxic substances, 4, 5, 8, 44
see also peripheral nervous system
Netherlands, pesticide regulation, 249
neural tube, 67, 70
neuritic plaques, 67
Neurobehavioral Evaluation System, 127
neurobehavioral tests
advantages and limitations of, 116, 128
in animals, 82, 112, 116-117, 171
in combination with NTE, 118
computer-based, 127–128
environmental factors in, 126
examiner factors in, 126
Finland Institute of Occupational Health approach, 126, 127
in humans, 70, 123-126, 137
observational, 112
psychological testing, 126
reproducibility of, 128
selection of techniques, 125–126
subject factors in, 126
World Health Organization approach, 126-127
neuroblastoma C-1300 cell lines, 124
neurofibrillary tangles, 67
neuromuscular disorders, exacerbation of, 70
neuromuscular junction, 66, 124, 338
neuronal membrane, 72
neuronal potentials, 118
neurons, 124, 338
anoxia, 67
degeneration, 54, 72, 203, 338
development of, 67
effects of toxic substances on, 9, 67
electrical properties, 118
loss of, 67, 68, 74, 107
neurotoxic substances acting on, 72–74
regeneration, 44, 67
retinal, 124
structure, 5, 65, 72
neuropathies
defined, 67
delayed, 204
from industrial chemicals, 49, 108
mixed, 70, 338
peripheral, 181
from pesticides, 291–292
neuropathological examination
of animals, 13, 110, 111, 114, 116, 118, 136, 172, 178, 194, 224-225
in combination with NTE, 118
costs of, 20, 224-225, 231
defined, 338
electrophysiological testing with, 119
evaluation of PMN assessment accuracy with, 204
FDA policy on, 194
with glial fibrillary acidic protein radioimmunoassay, 117
with operant behavior studies, 116
sensitivity of, 193
neuropathological tests, 338
advantages of, 13, 128, 137
in animals, 118–121, 137
brainstem auditory evoked responses, 119, 128
electroencephalography and electroneurography, 128
EPA research on, 82
in humans, 70, 128, 137
somatosensory evoked potentials, 120-121, 128
visual evoked potentials, 119–120, 128
neurotoxic esterase assay (NTE), 111, 117–1 18, 13&137, 178, 194,339
neurotoxic substances, 339
absorption, distribution, biotransformation, and excretion, 64, 108
Index .355

additive effects, 44, 64, 65
behavioral effects, 70
benefits of regulating, 228-230, 232
classes of, 71–76, 175
classification criteria, 175
detectors of, 199
determinants of toxicity, 7, 63
effects on nervous system, 12, 67–71; see also symptoms of neurotoxicity
evaluation in animals, 109–110
export policy, 57
health costs of, 228–230; see also specific conditions
incidents of poisoning, 47 (table)
lipophilicity of, 44, 64
multiple, interaction of, 64–65
number of, 3, 4, 43
releases by industry, 135
susceptibility to, 70–71
see also abused drugs; chemicals; industrial chemicals; pesticides; therapeutic drugs; and specific substances
neurotoxicology
defined, 63, 339
developmental, in animals, 114-116
fundamentals, 63–76
principles, 63-65
see also health effects
neurotransmitters
aging and, 67
classical, 66, 336
depletion of, 109
effects of abused drugs on, 51, 52, 74, 74
functions of, 65, 66, 339
hippocampal, 71
inhibition of, 6, 7, 67
neuropeptides, 66, 74
see also specific neurotransmitters
nicotine, 74
nitrogen oxides, 181, 182, 258
no observed adverse effect levels (NOAELs), 106, 146
defined, 147, 339
in dose-response assessment, 147–148, 153
in risk assessment, 147–149, 150–151
in standard setting, 187
techniques to determine, 114, 115, 118, 147
no observed effect levels (NOELs)
defined, 147, 339
in dose-response assessment, 147–148, 153
norepinephrine, 66, 74, 109
notification of unreasonable risk, 218
nurses, education of, 98–99
nutritional status, and toxicity, 70, 71, 108, 269
occupational exposures, 148
administrative controls, 336
to carbon disulfide, 256
epidemiological studies, 26, 128–129
ethical issues, 130, 131
at fabric production plant, 47, 49
Hopewell, Virginia, chemical plant workers, 50, 293
incidence of disease from, 125
to lead, 257, 269, 276
mercury removal from thermometers, 131
monitoring, 13, 133, 289
to organic solvents, 30, 257, 296-304
to pesticides, 45, 50, 267, 281–285, 289, 293, 294; see also pesticide poisonings
at plastic manufacturing plant, 47, 55–56
prevention of, 130-131, 267, 336
regulation of, 16; see also Occupational Safety and Health Act
research on, 256
vulnerability of workers, 9
Occupational Safety and Health Act, 56
exposure limit for mercury, 131
general duty clause, 302
MCL for lead in air, 278
protection of farmworkers under, 26, 250-252, 267, 284, 285, 288–289
regulatory authority, 16, 161
reporting requirements for adverse effects, 204
risk assessment approach, 161
standard setting under, 16, 28, 180, 185–187, 195, 267, 276
toxic substances regulated by, 161
Occupational Safety and Health Administration (OSHA), 177
adequacy of efforts of, 28, 30
economic analysis requirements, 303
enforcement of regulations, 30, 276
Hazard Communication Right-to-Know Standard, 285
permissible exposure limits, 185-187, 199, 203, 302-304
policy issues and options for, 28-30
regulatory authority of, 15–16, 28, 161, 185, 302
risk assessment applications, 150, 151, 216
occupational safety and health programs, 130
octadecyl phosphite, 166
Organochlorine insecticides, 49, 292–294
organoleptic effects, 182-183, 339
organophosphites, 166
organophosphorous pesticides, 292–293, 339
Neurotoxicity: Identifying and Controlling Poisons of the Nervous System

action on nervous system, 26, 50, 74, 290
animal tests for, 13, 106-107, 110, 117-1 18, 136-137, 171, 194,290
delayed effects, 117-118, 194, 199,204,284,290-291, 295
duration of exposure and toxicity, 44,67, 107
effects on nervous system, 6, 26, 49-50, 67, 73, 107, 117, 290-292,294,295
ethyl-p-nitrophenyl phosphonothionate, 150, 151
extent of testing of, 18, 171, 199, 204
in vitro tests of, 124
incidents of toxicity, 47,69, 284; see also pesticide poisoning
list of, by level of toxicity, 292-293
monitoring of exposures to, 134, 289
reentry intervals for farmworkers, 287
research needs on, 26, 284
study design for, 178
organotin, 47, 74, 257
ozone, 181
paint
fumes, toxicity of, 4,44,296
lead in, 8, 184, 189-191,257,267-269, 276-277
Papua New Guinea, pesticide import violations, 243,251
paralytic shellfish poisoning, 72
parquat, 250,251
Parkinson’s disease
environmental cause, 3, 54-55, 70, 108
mortality, 3, 55
MPTP as cause of, 3,51,54,72
research on, 259
particulate matter, 181, 182
pattern reversal evoked potentials, 119, 120, 128
pentachlorophenol, 250
People’s Republic of China research on neurotoxicity, 22,258, 260
perhexilline maleate, 74
peripheral nervous system
damage from pesticides, 291-292
function tests, 178
structure, 66, 339
vulnerability of, 73
permissible exposure limits (PELs), 28,30, 185-187, 199,203, 276,296,302-304,339
personality effects, see mood and personality
pest control, new approaches, 243,290,295,337
Pesticide Action Network, Dirty Dozen Campaign, 249-250
pesticide poisoning
and accidents, 285
Agent Orange, 295
of agricultural workers, 45, 50,267, 282-285, 288,289,294, 295
Bhopal, India, accident, 243
case studies of, 281-296
in children, 283, 284, 293
chlordecone (Kepone) in Hopewell, Virginia 47, 50, 293
container recycling and, 251
deaths from, 250,251,283,285,290, 294,295
in developing countries, 250, 260
diagnosis of, 50,289
dose and, 283,290-292,294
effects on nervous system, 6, 26, 49-50, 67, 73, 107, 117, 283-285,290-295
epidemiological studies of, 285,295
exposure route and, 283, 292-293
labeling violations and, 242-243,251
Lake Volta, Ghana, incident, 252
major incidents of, 47 (table)
mercury fungicides, 47-49
from methyl bromide, 294
from misuse in developing countries, 50,239,248-249,251, 252,253
monitoring of, 251-256, 289, 296
from organochlorines, 293
from organophosphates, 47,50,69,284,290-292
prevalence of, 248-249,252,283,284, 295
prevention of, 26,28,30,250-252,267, 284,286-289,295
recovery periods, 284, 290
reentry intervals and, 288
repackaging and, 243, 247,248, 251
reporting of illnesses related to, 50, 283, 289,295
pesticides, 339
active ingredients, 336
in adipose tissue, 133, 292-293
advertising, 251, 255-256
alternatives to use of, 243,290-291,295
banned, restricted, or unregistered, 21-22,173,237-238,240, 242, 249-250, 252, 253, 255, 261, 283, 288, 290, 292-295; see also Exports
Belgian regulatory policies, 246-247
Canadian regulatory policies, 245
cancellation/suspension of registration, 173
chlorphenoxy herbicides, 294-295
cholinesterase inhibitors, 290-292
data call-ins, 172, 173,203
defined, 49,281-282
detection of residues, 50
development, 225-226, 231-232
in developing countries, regulatory issues, 248-256, 260; see also exports of toxic substances; and specific countries
dioxin contamination of, 294
Experimental Use Permit, 170-171,337
exports of, 56-57, 237, 241-245
Federal Republic of Germany regulatory policies, 245-246
fishing with, 252
fumigants, 293-294
inert ingredients, neurotoxicity evaluations, 24, 288
innovation in, and neurotoxicity testing, 226-227
International Code of Conduct on the Distribution and Use of Pesticides, 242,243
international effects of U.S. export practices, 242-245
Japanese regulatory policies, 247-248
labeling, 171, 172,240,242-243,247, 248,253-255
market size worldwide, 237
MCLs for, 183
me-too registration, 240, 253,255,338
monitoring of, 132, 133, 134, 135, 241, 242, 251, 253-255, 289
neurotoxic, 43, 172, 183, 290-295
notification requirements, 22, 239-240, 247, 261, 290, 339
occupational exposures to, 281-283
organochlorine, 292-293
prior informed consent, 249,339
protective clothing, 250,283,287-289
pyrethroids, 72,295
reentry intervals for farmworkers, 284, 286-288, 290, 295-296, 340
registered, 3, 43, 49, 195, 237
registration of new compounds, 17, 161, 170-171, 197, 199, 216, 241, 287-288, 295
regulation of (Federal), 16, 17, 56, 164, 170-173, 204, 285-289
reregistration of existing compounds, 17, 171-173, 197, 241, 286, 287
research on neurotoxicity, 256, 257-258, 295
residues in domestic and imported food, 241-242, 251, 282
resistance of pests to, 243
risk standards, 25, 168, 241
risk-benefit analysis, 216, 217, 296
safety information, 287
safety, measure of, 221-222
special review of, 173, 197, 216
state regulation of, 289-290
testing for neurotoxicity, 17, 18, 115, 119, 170-173, 191-192, 194, 199, 204, 287, 295
Tolerance Assessment System, 135
tolerances, 27, 164, 168, 171, 216, 241, 247, 254, 341
use annually, 282, 295
WHO toxicity classification, 249, 254
see also carbamate insecticides; organophosphate pesticides
phenacyclidine, 9, 52, 71
phenylene diamines (unsubstituted), 179
Philippines
pesticide problems in, 251
regulatory issues in, 252-253
phosalone, 284
Phosdrin, 242, 284
phosphamidon, 284
phosphines, 175
Phosvel, incidents of poisoning, 47
photoreceptor cells, 124
physicians, education of, 98
Poison Prevention Packaging Act (PPPA)
control measures under, 187, 190-191
regulatory authority, 16, 161
risk assessment approach, 161
standard setting under, 180
toxic substances regulated by, 161
policy issues and options
for ADAMHA, 33
adequacy of regulatory framework, 23-31
adequacy of research framework, 31-35
confidential business information, 25
cosmetics testing, 28
for CPSC, 31
education and training of research and health-care professionals, 36
education of workers and public, 37-38
for EPA, 23-27, 31-32
for FDA, 27-28, 33-34
interagency coordination of research and regulatory programs, 35-36
international regulatory and research programs, 38-40
Material Safety Data Sheets, 30
monitoring of adverse health effects, 28, 30
neurotoxicity testing requirements, 24-25, 27-28
for NIH, 32-33
for NIOSH, 34-35
for OSHA, 28, 30
protection of agricultural workers, 26, 28, 30
statutory scope of neurotoxicity regulation, 26-27
polyaromatic hydrocarbons, 133
polychlorinated biphenyls (PCBs), 115, 180
incidents of poisoning, 47, 247
monitoring of, 133, 134
research on, 258
potentiation, 65, 339
Poultry Products Inspection Act, 241, 242
premanufacture notices, 17, 174-176, 194, 196, 197, 201-202, 219-220, 227, 247
prevention of exposure
adequacy of measures, 28, 30, 288, 289
educational programs, 30, 130
engineering controls, 13, 30, 267, 276, 296, 300, 301, 337
to lead, 8, 189-190, 277, 278, 281
to organic solvents, 30, 296, 300-302
to pesticides, 26, 250-252, 267, 284, 285-290, 295, 340
protective clothing and devices, 30, 250, 267, 283, 286, 288-289, 295, 300-302, 339
reentry levels for farmworkers, 284, 286, 288, 290, 295, 340
state programs, 289-290
training in handling of pesticides, 252, 255, 290
in workplace, 130-131, 300-302, 336
see also monitoring toxic substances
propylene, 14, 136
protective clothing and devices, 30, 250, 267, 283, 286, 288-289, 295, 300-302, 339
psilocybin, 74
psycho organic syndrome, 296
psychoactive drugs, 6, 10, 27, 44, 50
psychological testing, 126
psychosis, 71
Public Health Service Act, 167
Purkinje cells, 67
pyramidal cells, 68
pyrethroid pesticides, 72, 295
pyridine derivatives, 175
quaternary ammonium compounds, 175
quinone, 179
radionuclides, 182
rat glioma C-6 cell lines, 124
reentry levels for farmworkers, 284, 286, 288, 290, 295, 340
reference dose (RfD), 116, 148-149, 150, 153, 340
registration, see licensing and registration
regulations and regulatory issues
adequacy of regulatory framework, 201-203
administration of laws, 56, 160-161; see also specific agencies
application and notification procedures, 159; see also licensing and registration
in behavioral teratology, 115
consistency of protection, 17, 19, 194-196, 199-200
consistency of requirements, 16-17, 194
coordination and cooperation among agencies, 19, 176, 194,
Neurotoxicity: Identifying and Controlling Poisons of the Nervous System

198-199,200-201,205, 326-327
costs of compliance, 20, 201, 211, 215, 217–218, 220, 230
diversity of, 159
economic benefits of, 228–230
economic impacts of, 213–215
economic incentives, 161
effectiveness of regulatory programs, 203–204, 205,274,281
endpoint basis for, 56
expected and detected neurotoxicity, 201–203
expenditures by government, 215
export laws, 239–241
general toxicological considerations in, 194-199
of human research, 130
impact analyses, 211 n.1, 214, 220, 231
of industrial chemicals, 56
in industrialized countries, 245–248
international regulatory activities, 21–22, 115, 237–256
labeling, 172
for lead, 46, 273–281
measurements of effectiveness, 201
minimal data set, value of, 201
neurological considerations in, 18–19, 178, 199-201, 204
new initiatives, 191–194
new v, existing chemicals, 18, 196-198
nonregulatory factors affecting implementation, 159, 161, 162
for pesticides, 241-242,286-290
redundancy of effort among agencies, 198
risk assessment approaches, 146, 150–151
State regulation of lead, 277, 278
State regulation of pesticides, 289-290
statutory authority, 56; see also legislation; and specific statutes
tolerance setting, 164
see also cost-benefit analysis; economic issues
regulatory analyses, 20, 211, 218 n.11
institutionalization of, 215, 230
utility in regulatory policymaking, 220-221
regulatory impact analyses (RIAs), 211 n.1, 214, 216, 231
reporting of harmful effects, 180, 197
CPSA requirements, 204
FFDCA requirements, 167,203
OSH Act requirements, 204
pesticide poisoning, 50,283,289,295
of therapeutic drugs, 18, 167, 203
research
academic activities, 92–94, 256–259
adequacy of Federal programs, 31–35, 81
by charitable organizations, 97
under Clean Air Act, 180
comparison of U.S. and foreign programs, 259
coordination of Federal programs, 200, 325
development of methodologies, 81,259
Federal activities, 9, 11–12, 81–92, 321–324; see also specific agencies
funding, 9, 11-12, 81, 82-84,259
industry activities, 12, 94-95, 256-259
interactions among, government, academia, and industry, 96, 256-259
international efforts, 22, 256–260, 261
journals, 22,256
leadership roles by foreign governments, 260
needs, 3, 11,26,55,76, 137, 154–155, 259–260, 295
pathological changes related to functional impairment, 154
resources, 259
trends internationally, 21,258-259,261
workplace, 129; see also occupational exposures
see also academic research; epidemiological studies; industrial research
research scientists, education of, 12, 97, 259
Resource Conservation and Recovery Act (RCRA), 135, 176
cost-benefit analysis under, 216
control measures under, 187, 189–191
economic issues
export controls, 239, 240
regulatory authority, 16, 23, 161
risk assessment approach, 161
vulnerable populations, 8–9, 45
zero, 153, 168, 339
risk assessment
for acrylamide exposures, 150, 151,216
appropriate approach, 145–149, 150–151, 152, 153
characterization of, 56, 105, 106, 148-149, 150, 154; see also testing
components of, 145, 231
controversial issues in, 14-15, 146
coordination of programs, 326-327
defined, 13, 145,211,340
dose-response relationship, 147–148, 153–154
EPA guidelines, 116, 146, 150, 192
exposure assessment, 148
hazard identification, 147, 148, 152, 154
Integrated Risk Information System, 198
and latent adverse effects, 15, 151-152, 155
limitations of current approaches, 106, 151-152
MOS/MOE approaches, 149, 162, 181
regulatory approaches, 17, 25, 146, 150–151, 160-161
safety factors, 148-149, 153–154
uncertainty in, 149, 153, 154, 340, 341
risk-benefit analysis, 211, 216-217, 218 n.11, 286, 296, 340
risk management
defined, 13, 145,211,340
process of, 145, 149-150
purpose of, 149
risk balancing approach, 149–150
risk only approach, 149
technological control approach, 150
Rorschach Inkblot Test, 127
Safe Drinking Water Act (SDWA), 26
1986 amendments, 183
cost-benefit analysis under, 216
Index

regulatory authority, 16, 23, 160
risk assessment approach, 160
standard setting under, 180, 183–184, 278
toxic substances regulated by, 160
Santa Ana Dexterity Test, 127
saxitoxin, 72
Scandinavian counties
neurotoxicological research, 22, 256-259, 260, 261
regulatory policies in, 260, 261
researcher training, 259
schedule-controlled operant behavior (SCOB) tests, 13, 110, 111, 116-117, 136, 137, 178, 192, 224-225, 231, 340
scorpion toxin, 72
screening, 154, 340
adequacy of, for chemicals, 17
developmental neurotoxicity, 116
in EPA core test battery, 111
FDA policy on, 194
with functional observational battery, 82, 111, 112, 193
with in vitro tests, 13, 110, 136
for lead exposure, 270, 277, 278, 280, 281
with motor activity test, 82, 193
of pesticides, 199, 204
structure-activity relationships, 18, 175, 194, 203, 340
WHO Neurobehavioral Core Test Battery, 126-127
Senegal, pesticide import violations, 243, 251
sensory systems
effects of neurotoxic substances on, 46, 51–52, 272
evoked potentials, 118–119, 128, 337
functions of, 66
and motor functions, 70
neuron losses, 74
serotonin, 66
effects of abused drugs on, 9, 51–52, 74
short-term exposure limits, 302
significant new use rule, 174
silicon, and Alzheimer’s disease, 54–55
silver, 133
soil, lead in, 269, 280-281
solvents, see organic solvents
somatosensory evoked potentials, 119, 120–121, 128
South Korea, pesticide import problems, 243
Soviet Union, neurotoxicity research, 22, 258, 260
specimen banking
domestic and international programs, 132-133
nonhuman tissues, 133
spina bifida, 70
spinal cord
clioquinol effects on, 74
damage from pesticides, 291-292
degeneration, 55
development of, 67
functions, 66
standards and standard setting
action levels for contaminants in foods, 164, 241–242, 336
air quality, 180-181
for airborne contaminants, 181, 182, 185
carcinogenicity -based, 185
challenges to EPA authority, 162, 182 n.8
under Clean Air Act, 180-182
under Clean Water Act, 182–183
under Consumer Product Safety Act, 184
cost-benefit analysis, 181
drinking water, 183-184
economic considerations in, 199
emissions, 181, 182
exposure probability and, 195
features of laws, 159, 160-161
under Federal Hazardous Substances Act, 184
under Federal Mine Safety and Health Act, 185
under Federal Water Pollution Control Act, 182–183
hazard communication, 187
by international groups, 242
for lead, 271, 276, 278-279
litigation over validity of, 276
margin of safety in, 180-181, 338
maximum contaminant levels and maximum contaminant level goals, 183, 198, 278-279, 338
neurotoxicity considered in, 162
under Occupational Safety and Health Act, 185–187
for packaging, 190
permissible daily intakes, 189
permissible exposure limits, 28, 30, 185-187, 199, 203, 276, 296, 302-304, 339
for pesticide residues, 164
recommended exposure limits, 199, 302–303, 340
reentry intervals for farmworkers, 284, 286-288, 340
regulatory approach, 16, 159, 180
regulatory impact analysis, 181
reportable quantities, 187
under Safe Drinking Water Act, 183–184, 191
threshold limit values, 151, 185, 186, 199, 203, 341
and toxicity testing requirements, 180
water quality, 182
see also regulations and regulatory issues; and specific statutes
steroids, 70
stroke research, 259
structure-activity relationships, 17, 18, 25, 175, 194, 203, 340
styrene, 14, 136, 258, 299, 303
substance P, 66
substantial nigra, 6, 67, 72
Sudan, pesticide poisoning in, 251
sudden infant death syndrome, 10, 53
sulfur oxides, 181
sulfuric acid, 14, 136
sulfuryl fluoride, 120
Superfund Amendments and Reauthorization Act, 135
confidentiality under, 176
health effects contemplated by, 188
regulatory authority, 161
research authorized by, 188
risk assessment approach, 161
toxic substances regulated by, 161, 198
Sweden
human tissue monitoring, 132
Performance Evaluation System, 127
synapse, 66, 70
chemical communication at, 66
defined, 340
measurement of function at endings, 118, 124
synaptic cleft, 66, 340
synergism, 64, 65, 340

2,4,5-T, 250, 294, 295
2,4,5-TP, 183
tardive dyskinesia, 6, 44
TCDD, 294
Telone II, incidents of poisoning, 47
temik, 251
temperature, and toxicity, 109
testing
accuracy of PMN assessments, 204
computerized/automated techniques, 112–113
confidentiality issues in, 19, 176, 202, 218, 226
consent decrees for, 177, 197, 201, 202, 336
coordination of programs, 325–326
of cosmetics, 52, 54, 168, 196
criteria, 152
cross-species comparisons, 115–116
current extent of, 12, 16, 43, 52, 55, 56, 76, 151, 211
design, factors considered in, 105–109, 178, 199–200
in developing countries, 251–252
disincentives to, 174–175, 176
economic impacts of, 218; see also Costs of testing
endpoints, 109, 116, 125, 150, 152, 178
of exports, 240
extrapolation of results to other populations, 147, 153
FDA requirements, 163, 165–167, 192–194, 199
FIFRA guidelines, 115
flexibility in, 193, 200
of food additives, 52, 192–194
in industrialized countries (other than U.S.), 245, 246, 247–248
and innovation in drugs and pesticides, 226–227
interpretation of safety, 165
laboratory automation, 223
laboratory capabilities, 223
limitations of current tests, 122, 151–152
needs, identification of, 324
options for changes in requirements for, 24–25
personnel, 223
protocol requirements, 222
quality assurance, 222–223
reliability and sensitivity, 26, 115, 152, 191, 193
research on new methods, 81–84
standardization of, 324–325
statutory authority for, 159
stringency of, 17, 195–196
tiered approach, 18, 109–110, 154, 193, 200, 341
triggers for, 24
validation, 109, 111, 123–124, 168
WHO objectives, 106
see also animal tests; in vitro tests; human testing and studies;
risk assessment; screening
tetrachloroethylene, 14, 136
tetraethyl lead, incidents of poisoning, 47, 303
tetrodotoxin, 45, 72
Texas Agricultural Hazard Communication Law, 290
Thailand, pesticide misuse in, 243, 251
thalidomide, 73
thallium
effects on nervous system, 74
incidents of poisoning, 47
testing of, 124
toxicity, 48
water quality standards, 183
therapeutic drugs and biologics
adverse effects of, 29, 45, 50–51, 167–169
for animals, 166, 167
benefits assessment, 216
benzodiazepine hypnotics, 29, 169
efficacy and effectiveness, 217
interactions, 8, 29, 45, 169
investigational new drugs, 167–168, 203, 338
labeling, 29, 169
licensing and registration of, 18, 29, 161, 166–169
monitoring reactions to, 29, 168, 169
neuroeffective substances, 168
neurotoxic potential, 3, 45
new drug applications, 166, 167, 188, 339
packaging information on adverse effects, 28
R&D studies, 219
reporting of adverse reactions, 18, 167, 203
research on neurotoxicity, 258
risk assessment, 146, 151, 153
risk-benefit analysis, 217
safety, measure of, 221–222
seizure medication, 44
standard for approval, 166–167
testing of, 17, 18, 26, 29, 105, 115, 166–168, 169, 199, 204
see also specific drugs
thiamine deficiency, 71
thiocarbamates, 172
threshold limit values, 151, 185, 186, 199, 203, 341, 302–303
time-weighted average limits, 302
tin, 133
tissue culture
antibiotics added to, 123
applications in neurotoxicology, 122
defined, 122, 340
embryo, 123–124
expenditures for development of methods, 122
explants, 124, 337
organotypic, 124, 339
see also Cell culture; Organ culture
TOCP, incidents of poisoning, 47
tolerance levels
for contaminants in foods, 164
enforcement of, 241–242
lead in canned evaporated milk, 274–275
for pesticides residues, 27, 164, 171, 216, 239, 241
recommended approach, 27
toluene, 14, 119, 136, 183, 296, 299, 303
Total Diet Study, 135
toxaphene, 183, 250, 255, 292
toxic substances
general considerations in regulation of, 194–199
see also neurotoxic substances
Toxic Substances Control Act (TSCA), 56, 110
confidential business information under, 19, 25, 176, 202, 218, 226
consent decrees, 17, 177, 179, 197, 201, 202, 336
coordination of FIFRA neurotoxicity evaluations with, 191–192
economic balancing provisions of, 212, 216, 217–218
existing chemicals, 175, 177–180
export controls, 21–22, 239–240, 261
extent of testing under, 17, 18-19, 24-25, 201–202, 204
licensing and registration under, 16, 161, 173-180, 194, 195, 197
new chemicals, 174-175
notification requirement, 218, 239–240
regulatory authority, 16, 20, 160, 213
risk assessment approach, 160, 196
significant new use rule, 174
substances regulated by, 160
test guidelines, 150, 191, 199, 224
test rules, 17, 82, 197, 178, 179, 215, 217, 222, 340–341
Toxics Release Inventory, 13, 14, 17, 43, 122, 134-136, 197
triadimefon, 113
triazophos, 292
tributyl phosphorotrithioates, 173
1,1,l-rmchloroethane
 releases of, 14, 136
testing of, 115, 135, 179
trichloroethylene, 14, 136, 299, 303
2,4,5 -trichlorophenoxypropionic acid, 294
triethylene glycol monomethyl ethers, testing guidelines, 115, 179
trimethyl benzenes, 179
trihalomethanes, 183
trimethyltin
 biochemical markers for, 117
 poisoning, 6, 44, 68, 74
triorthocresyl phosphate, 47, 69
triphenyltin, 113
Tris phosphite, 166
United Kingdom
 regulatory policies in, 248
research on neurotoxicity, 21, 256,258, 259, 261
United Nations
 Food and Agriculture Organization, 135, 242, 243, 249–251, 253-256
 OECD toxicity testing guidelines, 191, 194
 urea-formaldehyde resins, 179
 U.S. Public Health Service, 189
vasopressin, 66
vincristine, 73
vinyl chloride, 182
visual evoked potentials, 119-120
visual systems
 impairment of, 26, 48, 49, 51, 55, 72, 74, 131, 135, 181
 substances affecting, 48, 49, 51, 55, 72, 74, 119
testing of, 119
vitamins, toxicity, 6, 44, 74
Walsh-Healy Act, 185, 186
water quality standards, 182–183
Wechsler Adult Intelligence Scale, 127
Wechsler Memory Scale, 127
World Health Organization, 22, 135, 242, 255
acceptable levels of lead, 271
childhood lead intoxication study, 257, 261
epidemiological study of dementia, 259
objectives of neurotoxicology testing, 106
Neurobehavioral Core Test Battery, 126-128
organic solvent studies, 257
pesticide toxicity classification, 249, 254
specimen banking program, 133
testing recommendations of, 114, 115, 116, 150
X-irradiation, 115
xylene, 14, 136, 299, 303
zinc pyridinethionine, 108
Zolone, 284